Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
technetium (99mTc) red blood cells
- Development stage
- Unknown
- Lead developer
- Curium
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Cell Therapies
- Administration
- Intravenous
01
Overview
Technetium (99mTc) red blood cells (commercially prepared using kits such as UltraTag RBC) is an autologous, radiolabeled blood-pool imaging agent. It is prepared in vitro by collecting a patient's autologous red blood cells, exposing them to stannous chloride to allow intracellular accumulation of stannous ions, and then adding sodium pertechnetate Tc-99m. The pertechnetate is reduced intracellularly, trapping the radioactive technetium-99m within the erythrocytes. Once reinjected intravenously, these tagged red blood cells remain within the intravascular space, allowing for gamma scintigraphic imaging. It is primarily indicated for cardiac blood pool imaging (including first-pass and gated equilibrium studies) and for the detection and localization of gastrointestinal bleeding sites.
- Brand names
- UltraTagUltraTag RBC
- Other names
- technetium Tc 99m red blood cellstechnetium Tc-99m red blood cellstechnetium-99m-labeled autologous erythrocytestechnetium99m-labeled autologous erythrocytestechnetium 99m-labeled autologous erythrocytestechnetium-99m-labeled red blood cellstechnetium99m-labeled red blood cellstechnetium 99m-labeled red blood cells
Beyond the preview
Go deeper on technetium (99mTc) red blood cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on technetium (99mTc) red blood cells.